당뇨병 케어용 임상 영양 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 병기별, 판매 채널별, 지역별 및 부문별 전망(2026-2033년)

The global clinical nutrition for diabetes care market size was valued at USD 2.4 billion in 2025 and is projected to grow from USD 2.5 billion in 2026 to USD 3.5 billion by 2033, growing at a CAGR of 4.8% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 34.0% in 2025. The increasing demand for specialized food products by individuals with diabetes or those at risk of developing the condition is a critical factor for the diabetes clinical nutrition market growth. This includes people with type 1 or type 2 diabetes, as well as those following a diabetic diet.

The rising prevalence of diabetes, driven by aging, obesity, sedentary lifestyles, and unhealthy dietary habits, is a major factor supporting the growth of the global clinical nutrition market. According to the International Diabetes Federation (IDF), approximately 589 million adults aged 20-79 years were living with diabetes worldwide in 2024, representing around 11.1% of the global adult population. This figure is projected to reach 853 million by 2050, reflecting the increasing global burden of the disease. Diabetes remains a leading cause of serious complications, including cardiovascular disease, chronic kidney disease, blindness, and lower-limb amputations, with risks increasing due to aging, obesity, physical inactivity, poor dietary habits, and inadequate glycemic control.

As the prevalence of diabetes and its associated complications continues to rise, healthcare providers are increasingly incorporating specialized clinical nutrition interventions to support glycemic control, improve nutritional status, and enhance long-term patient outcomes. Disease-specific medical foods, oral nutritional supplements, and enteral and parenteral nutrition play an important role in managing nutritional deficiencies and slowing disease progression in high-risk patients. Furthermore, a study by the University of Minnesota reported a 62% increase in the incidence of type 2 diabetes in the U.S. following the COVID-19 pandemic, particularly among children and adolescents aged 10-19 years, highlighting the growing need for effective nutritional management.

Growing consumer awareness, supportive public health initiatives, and increasing scientific evidence regarding the benefits of nutrition in diabetes management are further driving demand for diabetes-specific nutrition products. Consumers are increasingly seeking low-sugar, low-carbohydrate, and nutritionally balanced products that offer convenience without compromising taste, while many are willing to pay a premium for healthier alternatives. This shift in consumer preferences is expected to support sustained growth in the diabetes clinical nutrition market.

Global Clinical Nutrition for Diabetes Care Market Report Segmentation

This report forecasts revenue growth at the global, country, and regional levels, and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global clinical nutrition for diabetes care market report based on product, stage, sales channel, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)

Oral Nutrition

Parenteral Nutrition

Enteral Feeding Formulas

• Stage Outlook (Revenue, USD Million, 2021 - 2033)

Adult

Pediatric

• Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)

Online

Retail

Institutional Sales

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

North America

• U.S.
• Canada

Europe

• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway

Asia Pacific

• Japan
• China
• India
• Australia
• Thailand
• South Korea

Latin America

• Brazil
• Mexico
• Argentina

Middle East and Africa (MEA)

• South Africa
• Saudi Arabia
• UAE
• Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Stage
  • 1.2.3. Sales Channel
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product Outlook
  • 2.2.2. Stage Outlook
  • 2.2.3. Sales Channel Outlook
  • 2.2.4. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Global Clinical Nutrition for Diabetes Care Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
  • 3.2.3. Market opportunity analysis
• 3.3. Global Clinical Nutrition for Diabetes Care Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Global Clinical Nutrition for Diabetes Care Market: Product Estimates & Trend Analysis

• 4.1. Global Clinical Nutrition for Diabetes Care Market: Product Dashboard
• 4.2. Global Clinical Nutrition for Diabetes Care Market: Product Movement Analysis
• 4.3. Global Clinical Nutrition for Diabetes Care Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.4. Oral Nutrition
  • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Parenteral Nutrition
  • 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Enteral Feeding Formulas
  • 4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Clinical Nutrition for Diabetes Care Market: Stage Estimates & Trend Analysis

• 5.1. Clinical Nutrition for Diabetes Care Market: Stage Dashboard
• 5.2. Clinical Nutrition for Diabetes Care Market: Stage Movement Analysis
• 5.3. Clinical Nutrition for Diabetes Care Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.4. Adult
  • 5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Pediatric
  • 5.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Global Clinical Nutrition for Diabetes Care Market: Sales Channel Estimates & Trend Analysis

• 6.1. Global Clinical Nutrition for Diabetes Care Market: Sales Channel Dashboard
• 6.2. Global Clinical Nutrition for Diabetes Care Market: Sales Channel Movement Analysis
• 6.3. Global Clinical Nutrition for Diabetes Care Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.4. Online
  • 6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Retail
  • 6.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Institutional Sales
  • 6.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Global Clinical Nutrition for Diabetes Care Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.6. Denmark
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.8. Norway
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. China
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Japan
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.5. Thailand
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.6. South Korea
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.2. Mexico
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework/ reimbursement structure
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2025
  • 8.3.4. Abbott Nutrition
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Pfizer Inc.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Bayer AG
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Nestle Health Science S.A.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. GlaxoSmithKline plc
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Baxter International Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Otsuka Holdings Co., Ltd.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Mead Johnson & Company, LLC
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Danone Nutricia,
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Victus, Inc.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives